Clinical trialNCT05227703CompletedPhase 2Interventional

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

SponsorAbbVieEnrollment391Schizophrenia

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Julie Adams
AbbVie
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Bulgaria

Sofia, Sofia-Grad
Sofia, Sofia-Grad, Bulgaria
Burgas, Burgas
Burgas, Bulgaria
Pleven, Pleven
Pleven, Bulgaria
Sofia, Sofia
Sofia, Bulgaria

Hungary

Kalocsa, Bács-Kiskun
Kalocsa, Bács-Kiskun county, Hungary
Győr, Győr-Moson-Sopron
Győr, Győr-Moson-Sopron, Hungary
Budapest, Budapest
Budapest, Hungary

United States

Bentonville, Arkansas
Bentonville, Arkansas, United States
Bellflower, California
Bellflower, California, United States
la Habra, California
La Habra, California, United States
San Diego, California
San Diego, California, United States
Sherman Oaks, California
Sherman Oaks, California, United States
Torrance, California
Torrance, California, United States
New Haven, Connecticut
New Haven, Connecticut, United States
Homestead, Florida
Homestead, Florida, United States
Miami, Florida
Miami, Florida, United States
Miami Lakes, Florida
Miami Lakes, Florida, United States
Miami Springs, Florida
Miami Springs, Florida, United States
Atlanta, Georgia
Atlanta, Georgia, United States
Savannah, Georgia
Savannah, Georgia, United States
Chicago, Illinois
Chicago, Illinois, United States
Chicago, Illinois
Chicago, Illinois, United States
Berlin, New Jersey
Berlin, New Jersey, United States
Marlton, New Jersey
Marlton, New Jersey, United States
Charlotte, North Carolina
Charlotte, North Carolina, United States
Austin, Texas
Austin, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Jul 2022
Primary completion: 15 Aug 2024
Completion: 11 Sept 2024
Last update posted: 28 Oct 2025
Registered enrollment: 391
Registry id: NCT05227703

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.